STANNOXY-SUBSTITUTED METALLOCENE CATALYSTS FOR OLEFIN AND ACETYLENE POLYMERIZATION
    82.
    发明申请
    STANNOXY-SUBSTITUTED METALLOCENE CATALYSTS FOR OLEFIN AND ACETYLENE POLYMERIZATION 有权
    用于烯烃和乙烯聚合的硅烷取代的金属催化剂

    公开(公告)号:US20050113245A1

    公开(公告)日:2005-05-26

    申请号:US10723350

    申请日:2003-11-26

    摘要: This invention relates to the field of olefin polymerization catalyst compositions, and methods for the polymerization and copolymerization of olefins, including polymerization methods using a catalyst composition. One aspect of this invention is the formation and use of a catalyst composition comprising a stannoxy-substituted half-sandwich metallocene and an activator for olefin polymerization processes. For example, this invention encompasses the preparation of (η5-C5H5)Ti(OSnPh3)Cl2, its contact with an activator, for example, zinc-impregnated chlorided alumina, to form a catalyst composition, and the use of this catalyst composition for polymerizing olefins or acetylenes.

    摘要翻译: 本发明涉及烯烃聚合催化剂组合物领域,以及烯烃聚合和共聚方法,包括使用催化剂组合物的聚合方法。 本发明的一个方面是形成和使用包含苯氧基取代的半夹心金属茂和用于烯烃聚合方法的活化剂的催化剂组合物。 例如,本发明包括制备(η5 -C 5 H 5 H 5)Ti(OSnPh 3 N) )Cl 2,其与活化剂例如浸渍锌的氧化铝接触以形成催化剂组合物,以及使用该催化剂组合物来聚合烯烃或乙炔。

    CHIMERIC IMMUNORECEPTOR USEFUL IN TREATING HUMAN CANCERS
    85.
    发明申请
    CHIMERIC IMMUNORECEPTOR USEFUL IN TREATING HUMAN CANCERS 有权
    重要的免疫缺陷病毒治疗人类癌症

    公开(公告)号:US20120302732A1

    公开(公告)日:2012-11-29

    申请号:US13570032

    申请日:2012-08-08

    申请人: Michael Jensen

    发明人: Michael Jensen

    摘要: The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.

    摘要翻译: 本发明涉及嵌合跨膜免疫受体(命名为zetakines),其由细胞外结构域组成,所述细胞外结构域包含与能够将细胞外结构域连接至细胞表面的支持区连接的可溶性受体配体,跨膜区和细胞内信号结构域。 当在T淋巴细胞表面上表达时,Zetakines将T细胞活性直接导向表达可溶性受体配体特异性受体的那些特异性细胞。 替扎林嵌合免疫受体代表了用于重定向T细胞的抗原特异性的抗体型免疫受体的新型延伸,应用于各种癌症的治疗,特别是通过人类恶性利用的自身免疫/旁分泌细胞因子系统。 在一个优选的实施方案中是包含与IgG的Fc区连接的IL-13Rα2特异性IL-13突变体IL-13(E13Y)的细胞外靶向结构域的人胶质瘤特异性免疫受体,人CD4的跨膜结构域和人 CD3ζ链。

    Rotatable Wireline Tool of Enhanced Hydraulic Drive Consistency
    86.
    发明申请
    Rotatable Wireline Tool of Enhanced Hydraulic Drive Consistency 有权
    增强液压驱动一致性的可旋转电缆工具

    公开(公告)号:US20120145394A1

    公开(公告)日:2012-06-14

    申请号:US13316239

    申请日:2011-12-09

    IPC分类号: E21B29/00 E21B34/00

    摘要: A rotatable downhole cutting tool configured for enhanced drive consistency in low power circumstances. The tool is equipped with a hydraulic axial drive actuator suitable for use in wireline deployment. The actuator itself includes a reciprocating piston with a ball screw that threadably interfaces a ball nut for dampening the axial drive imparted by the piston. As such, even though hydraulically driven at generally well under about 10 horsepower, bounce in the axial drive is substantially eliminated. This is particularly advantageous where cutting is to be applied to downhole metal based obstructions.

    摘要翻译: 一种可旋转的井下切割工具,其配置为在低功率环境下提高驱动一致性。 该工具配备有适用于有线部署的液压轴向驱动执行器。 致动器本身包括具有滚珠丝杠的往复式活塞,该滚珠丝杠与滚珠螺母螺纹接合,以阻尼由活塞施加的轴向驱动。 因此,即使液压驱动通常在大约10马力以下,基本上消除了轴向驱动中的反弹。 这对于应用于井下金属的障碍物的切割是特别有利的。

    CHIMERIC IMMUNORECEPTOR USEFUL IN TREATING HUMAN CANCERS
    88.
    发明申请
    CHIMERIC IMMUNORECEPTOR USEFUL IN TREATING HUMAN CANCERS 有权
    重要的免疫缺陷病毒治疗人类癌症

    公开(公告)号:US20110223129A1

    公开(公告)日:2011-09-15

    申请号:US13046518

    申请日:2011-03-11

    申请人: Michael Jensen

    发明人: Michael Jensen

    摘要: The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human maligancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targeting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.

    摘要翻译: 本发明涉及由跨膜结构域组成的嵌合跨膜免疫受体,其包含与能够将细胞外结构域连接至细胞表面的支持区连接的可溶性受体配体,跨膜区和细胞内信号结构域。 当在T淋巴细胞表面上表达时,Zetakines将T细胞活性直接导向表达可溶性受体配体特异性受体的那些特异性细胞。 替扎林嵌合免疫受体代表了用于重定向T细胞的抗原特异性的抗体型免疫受体的新型延伸,应用于各种癌症的治疗,特别是通过人类恶性利用的自身免疫/旁分泌细胞因子系统。 在一个优选的实施方案中是包含与IgG的Fc区连接的IL-13Rα2特异性IL-13突变体IL-13(E13Y)的细胞外靶向结构域的人胶质瘤特异性免疫受体,人CD4的跨膜结构域和人 CD3ζ链。

    Chimeric immunoreceptor useful in treating human cancers
    90.
    发明申请
    Chimeric immunoreceptor useful in treating human cancers 审中-公开
    嵌合免疫受体可用于治疗人类癌症

    公开(公告)号:US20090257994A1

    公开(公告)日:2009-10-15

    申请号:US12314195

    申请日:2008-12-05

    申请人: Michael Jensen

    发明人: Michael Jensen

    摘要: The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an intracellular signalling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those specific cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors represent a novel extension of antibody-based immunoreceptors for redirecting the antigen specificity of T cells, with application to treatment of a variety of cancers, particularly via the autocrin/paracrine cytokine systems utilized by human malignancy. In a preferred embodiment is a glioma-specific immunoreceptor comprising the extracellular targetting domain of the IL-13Rα2-specific IL-13 mutant IL-13(E13Y) linked to the Fc region of IgG, the transmembrane domain of human CD4, and the human CD3 zeta chain.

    摘要翻译: 本发明涉及由跨膜结构域组成的嵌合跨膜免疫受体,其包含与能够将细胞外结构域连接至细胞表面的支持区连接的可溶性受体配体,跨膜区和细胞内信号结构域。 当在T淋巴细胞表面上表达时,Zetakines将T细胞活性直接导向表达可溶性受体配体特异性受体的那些特异性细胞。 Zetakine嵌合免疫受体代表了用于重定向T细胞的抗原特异性的基于抗体的免疫受体的新的延伸,其应用于治疗多种癌症,特别是通过人类恶性肿瘤使用的自身免疫/旁分泌细胞因子系统。 在一个优选的实施方案中是包含与IgG的Fc区连接的IL-13Ralpha2特异性IL-13突变体IL-13(E13Y)的细胞外靶向结构域的人胶质瘤特异性免疫受体,人CD4的跨膜结构域和人 CD3ζ链。